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Background: Acute massive pulmonary embolism(PE) is a life-threatening condition with high mortality.Survival depands on rapid recanalization of 
the pulmonary arterial occlusion and reduction of the right ventricular(RV) afterload.
The standard medical management for patients with massive PE is systemic thrombolysis. This treatment is associated with hemorrhagic risks, and 
some patients cannot receive systemic thrombolysis due to contraindications.
Catheter directed thrombolysis (CDT) is an alternative therapy for patients with massive PE with contraindications to systemic thrombolysis,and this 
method is considered to be much less invasive than the open surgery.A novel modified tissue-type plasminogen activator, monteplase, has been 
approved for acute massive PE in Japan 2005.
The purpuse of this study was to assess the efficacy and safety of CDT with monteplase.
Methods: Acute hemodynamic changes and clinical outcomes were assessed in 33 patients with angiographically confirmed massive PE. 
Thrombolysis with monteplase in combination with pulse-infusin-catheter(PIT) and thrombectomy was the acute phase treatment.
Results: The study population comprised 19 females and 13 males (mean age 66 years). All patients had RV overload; 6 patients presented in 
shock.
Procedual success was achieved in all patients. The mean dosage of monteplase was 85.8+/-39.5x104 IU.
After CDT,significant decrease of mean pulmonary artery pressure(36.4+/-9.4 to 30.1+/-8.0 mmHg:P=0.01) and Miller score(19.8+/-7.7 to 16.3+/-
7.4:P=0.04).
Furthermore,mean systemic blood pressure increased significantly(93.8+/-22.0 to 100.8+/-22.9 mmHg:P=0.02).
Death at 30 days occurred in 3 patients (9%). Major bleeding occurred in 1 patients (3%). No patients with RV overload at discharge.
Follow-up information after discharge was obtained for 30 patients.
(mean follow-up 33.9+/-17.5months)
All the patients were confirmed survive. Recurrent PE was not observed during follow-up period under anticoaglation.
Conclusions: CDT with monteplase is an effective and safe therapy for acute massive PE.
